FDA approves oncology drug that targets genetic driver of a tumor

The FDA has approved Rozlytrek, Roche's personalized cancer treatment that targets tumors with a specific genetic mutation.

The treatment targets certain types of solid tumors that show rare genetic defects called NTRK gene fusions. 

The treatment works regardless of where the tumor started in the body, according to a news release. 

This is the third oncology drug that targets a key genetic driver of cancer rather than a specific type of tumor. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars